MAPK
Catalog No.
Product Name
Application
Product Information
Citations
-
HPK1 Inhibitor
(3S,4R)-GNE-6893 is a selective inhibitor of HPK1, an important regulator in immune signaling pathways. This compound exhibits potent and orally bioavailable inhibition, making it a valuable tool for exploring the roles of HPK1 in cancer biology. Its biological activity provides insights for research applications focused on cancer therapeutics and immune modulation. -
MAP4K Inhibitor
GNE-220 is a potent and selective inhibitor of MAP4K4, exhibiting an IC50 of 7 nM. This compound plays a crucial role in modulating MAPK signaling pathways, making it valuable for studying cell proliferation and apoptosis. GNE-220 is applicable in research focused on cancer biology and inflammatory diseases, where MAP4K4 is implicated in disease progression. -
HPK1 Inhibitor
HPK1-IN-15 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), a member of the MAP4K family implicated in various signaling pathways. This compound is valuable for investigating the role of HPK1 in diseases such as cancer and for exploring potential therapeutic approaches to modulate HPK1 activity. Its specificity and potency make it an important tool in both basic research and drug development efforts targeting HPK1-related mechanisms. -
HPK1 Inhibitor
HPK1-IN-16 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), a member of the MAP kinase kinase kinase kinase (MAP4K) family. By specifically targeting HPK1, this compound demonstrates potential in the study of various diseases linked to HPK1 activity, including cancer. HPK1-IN-16 is valuable for research applications focused on the modulation of HPK1-related pathways to better understand disease mechanisms and explore therapeutic interventions. -
HPK1 Inhibitor
HPK1-IN-13 is a selective inhibitor of HPK1, a serine/threonine protein kinase implicated in hematopoietic progenitor cell signaling. As a member of the MAP4K family of mammalian Ste-20-related kinases, HPK1 plays a crucial role in various cellular processes. HPK1-IN-13 is designed for research applications targeting HPK1-related diseases, offering potential insights into its role in health and disease states. -
HPK1 Inhibitor
HPK1-IN-12 is a potent inhibitor of HPK1, a serine/threonine protein kinase that is part of the MAP4K family of mammalian Ste-20-related protein kinases. This compound selectively targets HPK1 and demonstrates significant inhibitory effects, making it a valuable tool for studying HPK1-related diseases. Its application in research can contribute to the understanding of the molecular mechanisms underlying various pathologies involving HPK1 signaling pathways. -
HPK1 Inhibitor
HPK1-IN-17 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), a member of the MAP kinase kinase kinase kinase (MAP4K) family. This compound is instrumental in investigating the role of HPK1 in various diseases, particularly in cancer, by modulating its activity. HPK1-IN-17 is valuable for research applications aimed at understanding HPK1's involvement in hematopoiesis and potential therapeutic interventions. -
HPK1 Inhibitor
HPK1-IN-14 is a selective inhibitor of HPK1, a serine/threonine protein kinase that is part of the MAP4K family and is found in hematopoietic progenitor cells. This compound exhibits significant potential for inhibiting HPK1 activity, making it a valuable tool for research into HPK1-related diseases and cellular signaling pathways. Researchers can utilize HPK1-IN-14 to investigate the roles of HPK1 in various biological processes and therapeutic contexts. -
HPK1 Inhibitor
HPK1-IN-11 is a potent inhibitor of HPK1, a serine/threonine protein kinase that is part of the MAP4K family of mammalian Ste-20-related protein kinases. This compound is valuable for investigating HPK1-related diseases and can facilitate research into the molecular mechanisms associated with these conditions. Its inhibitory properties make HPK1-IN-11 a critical tool for studying the role of HPK1 in various biological processes. -
HPK1 Inhibitor
HPK1-IN-10 is a potent inhibitor of the serine/threonine protein kinase HPK1, which is classified within the MAP4K family of mammalian Ste-20-related protein kinases. This compound demonstrates significant biological activity by modulating the signaling pathways associated with HPK1, making it a valuable tool for investigating HPK1-related diseases. Research applications include the study of immune responses and potential therapeutic interventions in related pathologies. -
HPK1 Inhibitor
HPK1-IN-18 is a potent and selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), a member of the MAP kinase kinase kinase kinases (MAP4Ks) family. This compound demonstrates significant biological activity by modulating HPK1 signaling pathways, making it a valuable tool for research into cancer and other disorders associated with HPK1 activity. Its application can aid in elucidating the role of HPK1 in various biological processes and potential therapeutic interventions. -
HPK1 Inhibitor
HPK1-IN-31 is a potent hematopoietic progenitor kinase 1 (HPK1) inhibitor, exhibiting an IC50 value of 0.8 nM. This compound demonstrates significant anti-tumor activity, making it a valuable tool in cancer research. Its ability to modulate immune responses further enhances its potential applications in immunological studies. -
HPK1 Antagonist
HPK1 antagonist-1 (I-792) is a selective antagonist of HPK1, a key regulator involved in immune signaling pathways. This compound exhibits significant biological activity by inhibiting HPK1-mediated signaling, making it a valuable tool for investigating its role in cancer progression and immune disorders. Researchers can utilize HPK1 antagonist-1 to explore therapeutic strategies targeting HPK1 in various disease models. -
HPK1 Kinase Inhibitor
HPK1-IN-21 is a potent inhibitor of HPK1 kinase, exhibiting a Ki value of 0.8 nM. This compound demonstrates significant biological activity in modulating immune responses through inhibition of T-cell signaling pathways. HPK1-IN-21 is of particular interest for research applications in cancer immunotherapy and the study of autoimmune diseases. -
HPK1 Inhibitor
HDM2004 is a selective inhibitor of HPK1, demonstrating potent activity with an IC50 of 1.89 nM. This compound is orally bioavailable and effectively penetrates the blood-brain barrier, exhibiting notable anticancer activity against colon cancer. Additionally, HDM2004 shows synergistic effects when used in combination with anti-PD-L1 in syngeneic mouse models, making it a valuable tool for research into colon cancer therapies. -
HPK1 Inhibitor
HMC-B17 is a selective inhibitor of HPK1, exhibiting an IC50 of 1.39 nM. It enhances the secretion of IL-2 in Jurkat cells, with an EC50 of 11.56 nM, thereby potentiating the efficacy of anti-PD-L1 therapies. This compound is valuable for research into cancer mechanisms and immunotherapy strategies. -
HPK1 Inhibitor
HPK1-IN-36 is a potent inhibitor of HPK1, exhibiting an IC50 value of 0.5 nM. This compound selectively targets the HPK1 signaling pathway, which plays a crucial role in T cell activation and immune response regulation. HPK1-IN-36 is valuable for research applications aimed at understanding immune modulation and investigating potential therapies for autoimmune diseases and immune-related disorders. -
HPK1 Inhibitor
HPK1-IN-41 is a potent inhibitor of the HPK1 protein, exhibiting an IC50 value of 0.21 μM. This compound is instrumental in research focused on diseases linked to HPK1 activity, enabling studies on its role in various cellular processes and potential therapeutic interventions. Its utility in modulating HPK1 makes it a valuable tool for exploring targeted treatments in related pathologies. -
HPK1 Ligand
HPK1 ligand 6 is an effective ligand for Hematopoietic Progenitor Kinase 1 (HPK1), targeting its regulatory pathways. This compound plays a crucial role in cellular signaling and immune responses, making it a valuable tool for studying the functions of HPK1. Additionally, HPK1 ligand 6 can be utilized to synthesize PROTAC HPK1 Degrader-6, facilitating research into targeted protein degradation and therapeutic applications in various diseases. -
HPK1 Inhibitor
HPK1-IN-27 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1), a serine/threonine kinase within the MAP4K family. This compound modulates critical signaling pathways involved in cell proliferation and survival, making it a valuable tool for cancer research. Its ability to inhibit HPK1 activity contributes to investigations into the mechanistic roles of this kinase in tumorigenesis and potential therapeutic interventions. -
HPK1 Inhibitor
HPK1-IN-28 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1), which functions as a negative regulator in the activation of dendritic cells, T cells, and B cells. This compound enhances anti-tumor immunity, making it a valuable tool for research in immune-related diseases, particularly in tumor immunology. HPK1-IN-28 offers significant potential for investigating therapeutic strategies aimed at modulating immune responses. -
HPK1 Inhibitor
HPK1-IN-35 is a potent and selective inhibitor of HPK1, demonstrating an IC50 value of 3.5 nM. This compound effectively reduces the phosphorylation of SLP76 while promoting the secretion of interleukin-2 (IL-2). HPK1-IN-35 is particularly valuable for research in T cell activation and immune response modulation. -
HPK1 Inhibitor
HPK1-IN-49 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an IC50 value exceeding 100 nM. This compound is utilized in research to study the role of HPK1 in various cellular processes, including immune responses and signal transduction pathways. Its inhibition can provide insights into therapeutic strategies targeting HPK1-related diseases. -
HPK1 Inhibitor
HPK1-IN-29 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), a key negative regulator in the activation of dendritic cells, T cells, and B cells. By inhibiting HPK1, this compound enhances anti-tumor immune responses. HPK1-IN-29 is valuable for research into immune-related diseases, particularly in the context of cancer immunotherapy and tumor microenvironment modulation. -
HPK1 Inhibitor
HPK1-IN-52 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an IC50 value of 10.4 nM. This compound demonstrates significant anti-tumor activity, making it a valuable tool for studying the role of HPK1 in cancer biology. HPK1-IN-52 can be utilized in various research applications aimed at elucidating therapeutic strategies targeting HPK1-mediated pathways. -
HPK1 Inhibitor
HPK1-IN-9 is a potent inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), a serine/threonine protein kinase associated with the MAP4K family of Ste-20-related protein kinases. This compound demonstrates significant biological activity in modulating HPK1 signaling pathways, making it a valuable tool for research into HPK1-related diseases. Researchers investigating the roles of HPK1 in various cellular processes may find HPK1-IN-9 particularly useful for elucidating its potential therapeutic implications. -
HPK1 Inhibitor
HPK1-IN-38 is a selective inhibitor of MAP4K1, also known as HPK1. This compound exhibits potent inhibition of HPK1's kinase activity, making it a valuable tool for studying HPK1-related biological processes. Its application is particularly relevant in research focused on immune response modulation and cancer biology, where HPK1 plays a critical role. -
HPK1 Inhibitor
HPK1-IN-20 is a specific inhibitor of hematopoietic progenitor kinase 1 (HPK1), which plays a critical role in immune signaling pathways. This compound demonstrates strong inhibition of HPK1 activity, which may enhance T cell activation and proliferation. It is suitable for research applications focused on immunological studies and potential therapeutic development for immune-related disorders. -
MAP4K1/HPK1 Inhibitor
HPK1-IN-37 is a selective inhibitor of MAP4K1/HPK1, demonstrating an IC50 of 3.7 nM. Its potent inhibitory activity makes it a valuable tool for investigating HPK1-related disorders, including various cancer types. Researchers can utilize HPK1-IN-37 to elucidate the role of HPK1 in signal transduction pathways and therapeutic interventions. -
MAP4K Inhibitor
BAY-405 is a potent MAP4K1 inhibitor that demonstrates nanomolar activity in both biochemical and cellular assays. Its effective inhibition of MAP4K1 has significant implications for research into pathways regulated by this kinase, making it a valuable tool for studying cellular processes such as proliferation, differentiation, and stress response. Additionally, BAY-405 is capable of achieving in vivo exposure following oral administration, enhancing its utility in preclinical studies. -
HPK1 Inhibitor
HPK1-IN-30 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1), a serine/threonine kinase belonging to the MAP4K family. This compound demonstrates significant biological activity by modulating HPK1 signaling pathways, which are implicated in various cancers. HPK1-IN-30 is valuable for research applications focused on cancer biology and therapeutic development targeting the HPK1 pathway. -
HPK1 Inhibitor
HPK1-IN-33 is a potent inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), exhibiting a Ki value of 1.7 nM. This compound effectively inhibits IL-2 production, demonstrating an EC50 of 286 nM in Jurkat wild-type cells and greater than 10,000 nM in Jurkat HPK1 knockout cells. HPK1-IN-33 is applicable in studies focused on immune response modulation and therapeutic interventions targeting T cell activation. -
HPK1 Inhibitor
HPK1-IN-55 is a highly selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), exhibiting an IC50 of less than 0.51 nM. This compound demonstrates significant selectivity for HPK1, with over 637-fold selectivity against GCK-like kinases and over 1022-fold against LCK. HPK1-IN-55 has been shown to possess anticancer properties, making it a valuable tool for research into cancer therapies and the regulation of hematopoietic cells. -
HPK1 Inhibitor
HPK1-IN-60 is an inhibitor of the HPK1 protein kinase, which plays a critical role in regulating T cell activation. This compound exhibits significant potential in antitumor immunotherapy research by modulating immune responses. It is a valuable tool for studying the mechanisms of immune regulation and exploring therapeutic strategies in cancer treatment. -
HPK1 Inhibitor
HPK1-IN-42 is a potent inhibitor of HPK1, exhibiting an IC50 value of 0.24 nM. This compound is valuable for studying the regulation of T cell receptor signaling and its implications in immune responses. Its use in research can advance understanding of HPK1's role in cellular processes and therapeutic strategies for immune-related diseases. -
HPK1 Inhibitor
HPK1-IN-54 is a selective inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), significantly enhancing T cell activation and proliferation. With an IC50 value of 2.67 nM, it demonstrates over 100-fold selectivity against the MAP4K family and over 300-fold selectivity for other kinases. This compound exhibits potent antitumor effects, evidenced by strong efficacy in a CT26 murine colon cancer model and the ability to synergize with anti-PD-1 therapies. HPK1-IN-54 offers a valuable tool for research in immunotherapy applications. -
HPK1 Inhibitor
HPK1-IN-24 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1) with a Ki value of 100 nM. This compound is designed for applications in cancer research, where targeting HPK1 may enhance the understanding of tumorigenesis and cellular signaling pathways. Its inhibition of HPK1 allows for the exploration of novel therapeutic strategies in oncology. -
MAP4K4 Inhibitor
PF-06260933 hydrochloride is a selective inhibitor of the MAP4K4 kinase, demonstrating an IC50 of 3.7 nM in enzymatic assays and 160 nM in cellular studies. This compound is orally active and is utilized in research focused on understanding the signaling pathways associated with MAP4K4. Its inhibition of MAP4K4 positions it as a valuable tool for investigating therapeutic strategies in diseases linked to aberrant MAP4K4 activity. -
HPK1 Inhibitor
HPK1-IN-46 is a selective inhibitor of HPK1, demonstrating an IC50 value of 1.1 nM. This compound effectively inhibits SLP76 phosphorylation mediated by HPK1, resulting in the reversal of T-cell inhibition and an enhancement of anti-tumor immunity. HPK1-IN-46 is valuable in immunotherapy research for tumors, particularly in exploring T-cell regulatory mechanisms and tumor microenvironment interactions. -
HPK1 Inhibitor
HPK1-IN-25 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an enzymatic activity IC50 of 129 nM. This compound is valuable for cancer research, as HPK1 plays a significant role in regulating cell proliferation and apoptosis. Researchers may utilize HPK1-IN-25 to investigate its effects on tumor growth and lymphocyte signaling pathways. -
MAPKAPK5 Inhibitor
MAPKAPK5-IN-1 is a specific inhibitor of MAPKAPK5, a key regulator involved in inflammatory pathways. This substituted triazolopyrazine compound demonstrates potent inhibition of MAPKAPK5 activity, making it a valuable tool for studying the molecular mechanisms underlying rheumatoid arthritis and related inflammatory conditions. Its application in research could provide insights into potential therapeutic targets for these diseases. -
MAPKAPK2 (MK2) Inhibitor
RMM-46 is a selective inhibitor of MAPKAPK2 (MK2), functioning as a reversible covalent modulator. It demonstrates significant biological activity in inhibiting MSK/RSK-family kinases, making it a valuable tool for research focusing on cellular signaling pathways. RMM-46 is particularly useful in studies related to cancer biology and stress response mechanisms, facilitating a deeper understanding of MK2's role in various physiological and pathological conditions. -
MEK Inhibitor
Trametiglue is a highly selective MEK inhibitor that targets both KSR-MEK and RAF-MEK pathways. It demonstrates exceptional potency through unique interfacial binding interactions, making it a valuable tool for investigating MEK-related signaling in various cancer models. Trametiglue is suitable for research applications focused on cancer biology, drug resistance mechanisms, and the development of targeted therapies. -
MEK inhibitor
Atebimetinib is a novel dual MEK inhibitor that targets the MEK signaling pathway, playing a critical role in cellular proliferation and survival. It demonstrates significant anti-pancreatic cancer activity, making it a valuable reagent for cancer research. This compound is suitable for studies focused on understanding MEK-related signaling mechanisms and developing targeted therapies for pancreatic and other cancers. -
MEK Inhibitor
Luvometinib is a selective MEK inhibitor that demonstrates antitumor activity by inhibiting the MAPK/ERK signaling pathway. It is employed in research focused on cancer biology, particularly in the study of various malignancies characterized by aberrant MEK signaling. Luvometinib is valuable for investigating therapeutic strategies aimed at enhancing targeted cancer treatments. -
MEK Inhibitor
MEK4 inhibitor-1 is a selective MEK4 inhibitor that demonstrates potent activity against pancreatic adenocarcinoma with an IC50 value of 61 nM. This compound is utilized in research to investigate the role of MEK4 signaling in cancer progression and therapeutic resistance. Its application in preclinical studies can provide insights into potential treatment strategies targeting MEK4 in various malignancies. -
MEK
(2Z,3Z)-U0126 is a selective non-competitive inhibitor of MEK1 and MEK2, exhibiting potent anti-inflammatory properties with IC50 values of 72 nM for MEK1 and 58 nM for MEK2. This compound effectively inhibits anchorage-independent growth in Ki-ras-transformed rat fibroblasts by interfering with the extracellular signal-regulated kinase and mammalian target of rapamycin signaling pathways. It also has the potential to undergo isomerization and cyclization, leading to various derivatives with lower affinity for MEK and reduced inhibition of AP-1 activity compared to the original compound. -
MEK Inhibitor
Envometinib is a dual MEK inhibitor that utilizes Deep Cyclic Inhibition (DCI) as its primary mechanism of action. It demonstrates significant antitumor activity across various in vivo models, making it a valuable tool for cancer research. Envometinib is particularly relevant for studies involving RAS and RAF mutated cancers, such as colorectal cancer and melanoma. -
MEK Inhibitor
MEK-IN-7 is a potent, orally available, and selective inhibitor of MEK1, demonstrating an IC50 of 29.62 nM. This compound effectively inhibits the proliferation of HT29 and A375 cancer cell lines, with IC50 values of 0.62 nM and 0.40 nM, respectively. Additionally, MEK-IN-7 has been shown to suppress tumor growth in HL-29 xenograft mouse models, making it a valuable reagent for research in melanoma and colon cancer. -
MEK5 Inhibitor
GW284543 hydrochloride is a selective inhibitor of MEK5, a key regulator in the MAPK signaling pathway. This compound effectively reduces phosphorylated ERK5 (pERK5) levels while decreasing the endogenous MYC protein. It is valuable for research applications investigating cellular signaling pathways, tumor biology, and potential therapeutic targets in various cancers.
